More specifically, it seems to be a combination of: documenting the medical needs of patients (probably through intake forms) who are experiencing or have experienced nausea, vomiting, or other drug tolerance-related issues associated with GLP-1s (which are discussed in this Hims paper), and providing personalized compounded semaglutide in doses outside the 10% threshold to address those documented medical needs
Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis
Disclaimer: Laboratory testing is informational and should be interpreted with symptoms, medical history, medication use, and guidance from a qualified healthcare provider
Second, each step is held for about four weeks before considering the next, which is what gives the GI system time to adapt
Which GLP-1 medications commonly cause diarrhea